Project Grant R01CA305981
Award Date 5/4/26
Completion Date 4/30/31
Dollars Obligated $713K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98109, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $716,521 to Sloan-Kettering Institute for Cancer Research on August 25, 2025, under the Cancer Treatment Research program (CFDA 93.395). The award supports the development and clinical evaluation of DLL3-targeted IL18-secreting chimeric antigen receptor (CAR) T cells for treating small cell lung cancer (SCLC). The research initiative addresses a critical clinical need, as SCLC currently demonstrates...
- Federal Project Grant Award Summary Fred Hutchinson Cancer Center received $737,945 in project grant funding from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) for the period of May 4, 2026, through April 30, 2029. The project, titled "Measuring Provider and Intervention Characteristic Determinants of Evidence-Based Cancer Care," will develop flexible, quantitative measurement tools using Item Response Theory (IRT) to assess...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Fred Hutchinson Cancer Center $169,776 under the Cancer Research Manpower program (CFDA 93.398) for a two-year project (August 1, 2025–July 31, 2027) titled "Unraveling Myeloid-Mediated Mechanisms of Immunotherapy Resistance in Prostate Cancer Bone Metastases at Single-Cell Resolution." This project grant funds biomedical research training and investigator-initiated research focused on identifying and...
- Federal Project Grant Award Summary The National Cancer Institute awarded H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. a Project Grant totaling $433,256 under the Cancer Treatment Research program (CFDA 93.395) for the period of June 1, 2026 through May 31, 2028. The research project focuses on discovering novel therapeutic targets and chemical leads to overcome epithelial-to-mesenchymal transition (EMT)-mediated resistance in epidermal growth factor receptor...
- Federal Project Grant Award Summary Weill Medical College of Cornell University received a $472,730 project grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective August 1, 2025, through July 31, 2030. This five-year project investigates the role of the tumor suppressor KEAP1 (Kelch-like ECH-associated protein 1) in antitumor immunity, with specific focus on understanding how loss-of-function KEAP1 mutations contribute to immune...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $136,266 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) effective July 14, 2025, through June 30, 2027. The grant funds research aimed at identifying therapeutic strategies to prevent small cell lung cancer (SCLC) histological transformation in epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma patients. The research focuses on understanding the...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Fred Hutchinson Cancer Center a $140,854 Project Grant under the Cancer Research Manpower program (CFDA 93.398) effective July 1, 2025, through December 31, 2026. This K99/R00 Pathway to Independence Award supports research training and career development for Dr. Karl Cristie Figuracion, PhD, ARNP, a postdoctoral research fellow transitioning to an independent scientist. The award funds a structured training and mentorship...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $483,395 Project Grant under the Cancer Treatment Research program (CFDA 93.395) beginning September 1, 2025, and concluding August 31, 2027. This research initiative focuses on investigating P300 and CBP (Cyclic AMP-Response Element Binding Protein) as novel therapeutic targets in renal cell carcinoma (RCC), specifically clear cell RCC (ccRCC). The project will examine the therapeutic potential...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Fred Hutchinson Cancer Center a Project Grant totaling $139,184 under the Cancer Research Manpower program (CFDA 93.398) for the period of July 1, 2025, through June 30, 2027. This award funds research investigating the role of RNA components of the translation apparatus in prostate cancer plasticity and therapy response. The project focuses on elucidating how prostate cancer leverages transfer RNA (tRNA) and 5'...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $186,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 23, 2025, with a completion date of May 31, 2027. The award supports pilot and feasibility studies for NN-01-195, a novel tumor-targeted Aurora-A kinase (AURKA) inhibitor developed through a drug conjugate approach. The research involves preclinical evaluation of this chimeric compound, which fuses an...